eoadjuvant trastuzumab and nab-paclitaxel for HER2 positive breast cancer.
Phase 2
Recruiting
- Conditions
- HER2 positive breast cancer
- Registration Number
- JPRN-UMIN000005210
- Lead Sponsor
- Keio University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) During pregnancy or lactation 2) Previous (written 5 years) or current history of malignant neoplasm 3) Sever bone marrow suppression, renal dysfunction, and liver dysfunction . 4) Long-term corticosteroid therapy 5) Sever cardiovascular or pulmonary disease. 6) Drug allergy to nab-paclitaxel or paclitaxel and albumin.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary endpoint : The pathological CR rate
- Secondary Outcome Measures
Name Time Method Secondary endpoint : The clinical response rate, adverse event, breast conserving rate and relapse free survival.